Patients with mild cognitive impairment with Lewy bodies (MCI-LB) who had abnormal EEG readings, a smaller insula on MRI, and elevated plasma tau and GFAP were more likely to progress to dementia sooner and to decline faster on cognitive testing, according to a study published in Parkinsonism & Related Disorders. The research combined three types of measurement, electrical brain activity, brain imaging, and blood proteins, in the same group of patients rather than looking at each on its own, an approach the authors say better reflects the several disease processes thought to drive Lewy body disease. Specifically, a reduced EEG dominant frequency, increased relative delta and theta power on EEG, reduced insula volume on MRI, higher plasma tau, and higher plasma GFAP were each associated with an increased hazard ratio for dementia or death. MCI-LB is considered a prodromal, or pre-dementia, stage of dementia with Lewy bodies, and identifying who within that stage is likely to decline fastest has been a gap in prior work on Lewy body progression, which has largely tracked biomarkers one at a time rather than in combination. The authors frame the multimodal panel as a step toward stratifying patients for future prognosis and for enrollment in clinical trials, rather than as a tool ready for clinic use. A companion analysis from the same research group, published in Movement Disorders, had already reported that individual plasma markers, NfL, GFAP and pTau181, tracked with faster cognitive decline and higher dementia risk in MCI-LB, and the new paper builds on that by adding EEG and MRI measures to the same patients to see whether combining modalities sharpens the prognostic signal.
Combined EEG, MRI and Blood Markers Flag Faster Decline in Early Lewy Body Disease
A study of patients with mild cognitive impairment linked to Lewy bodies finds that abnormal brain wave patterns, smaller insula volume, and higher blood tau and GFAP together tracked a shorter dementia-free survival, though the finding needs testing in larger groups before it could guide care.
The authors say the panel, if validated in independent and larger cohorts, could eventually help identify which patients with this prodromal diagnosis are most likely to progress quickly, information that could matter for planning care or for selecting participants in trials of experimental treatments.